- Marketwired•last yearAfter Successful Formulation Work, Cannabis Science Follows Through With a Full Clinical Drug Development Agreement With ImmunoClin to Deliver GMP Quality Pre-Clinical Data to Enter CS-NEURO-1 Into a Phase I Human Study in Europe
Cannabis Science, Inc. , a U.S. company specializing in the development of cannabis-based medicines, today announced that it has entered into a comprehensive clinical drug development to focus on delivering ...
- Marketwired•2 years agoSpotlight Innovation Subsidiary Celtic Biotech Prepares to Start Part 2 of Phase I Intravenous Crotoxin Clinical Study
Spotlight Innovation Inc. announces today that its subsidiary Celtic Biotech has started preparations to conduct Part 2 of the Phase I clinical study, Crotoxin in Patients with Advanced Cancer using an ...
- Marketwired•2 years agoImmunoClin Ltd. to Provide Contract Research Organization (CRO) Services for Crotoxin Phase I Part II Clinical Trials for Spotlight Innovation Subsidiary Celtic Biotech
Spotlight Innovation Inc. announces today that ImmunoClin Ltd. will act as its Contract Research Organization for its subsidiary Celtic Biotech Iowa, Inc.'s Part II of its Phase I clinical trial, Crotoxin ...
IMCL : Summary for IMMUNOCLIN CORP - Yahoo Finance
ImmunoClin Corporation (IMCL)
OTC BB - OTC BB Delayed Price. Currency in USD
Add to watchlist
At close: 9:31AM EST
|Day's Range||0.00 - 0.00|
|52 Week Range|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-0.20|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|